Drugs / Low Sodium Oxybate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06950281 | Jan 2026 → Dec 2027 expected | cluster headache syndrome | Leiden University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07077278 | Oct 2025 → Sep 2027 expected | idiopathic hypersomnia, postural orthostatic tachycardia syndrome | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05837091 | Feb 2024 → Jan 2027 expected | idiopathic hypersomnia | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Low Sodium Oxybate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06950281 ↗ |
| Known as | LXB | “Low sodium oxybate (LXB) will be administered as a twice nightly regimen.” NCT06950281 ↗1“Low sodium oxybate (LXB)” NCT07077278 ↗ |
| Route | Oral | “JZP-258 is an oral solution containing LXB” NCT06950281 ↗ |